Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

CAR-T Cell Therapy for Desensitization in Kidney Transplantation

Phase 1

Recruiting

Conditions: End Stage Renal Failure on Dialysis
Kidney Failure
Kidney Transplant

Interventions: Drug: Cyclophosphamide
Biological: CART-BCMA
Biological: huCART19
Drug: Fludarabine

First Posted Date: 2023-09-28

Last Posted Date: 2025-06-13

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 20

Registration Number: NCT06056102

Locations: 🇺🇸
Massachusetts General Hospital: Transplantation (Site #: 71107), Boston, Massachusetts, United States
🇺🇸
NYU Langone Health (Site #: 71177), New York, New York, United States
🇺🇸
University of Pennsylvania Medical Center (Site #: 71111), Philadelphia, Pennsylvania, United States

Advancing Transplantation Outcomes in Children

Phase 2

Recruiting

Conditions: Kidney Transplant

Interventions: Drug: Sirolimus
Drug: Mycophenolate Mofetil
Biological: Belatacept
Drug: Tacrolimus (Group 2)
Drug: Tacrolimus (Group1)
Drug: Anti-Thymocyte Globulin (ATG)

First Posted Date: 2023-09-28

Last Posted Date: 2025-06-26

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 200

Registration Number: NCT06055608

Locations: 🇺🇸
University of Alabama at Birmingham (Site # 71038), Birmingham, Alabama, United States
🇺🇸
Children's Hospital of Los Angeles (Site #: 71036), Los Angeles, California, United States
🇺🇸
Cedars-Sinai Medical Center (Site #: 71026), Los Angeles, California, United States

and more 17 locations

Tocilizumab in Lung Transplantation

Phase 2

Recruiting

Conditions: Lung Transplant

Interventions: Drug: Placebo for Tocilizumab
Drug: Tocilizumab

First Posted Date: 2023-09-13

Last Posted Date: 2025-06-18

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 350

Registration Number: NCT06033196

Locations: 🇺🇸
Boston Children's Hospital and Harvard Medical School (Site #: 71001), Boston, Massachusetts, United States
🇺🇸
Cleveland Clinic (Site #: 71101), Cleveland, Ohio, United States
🇺🇸
St. Joseph's Hospital and Medical Center (Site #: 71192), Phoenix, Arizona, United States

and more 11 locations

A Trial to Evaluate an HIV Envelope Trimer, N332-GT5 gp140, Adjuvanted With SMNP in Adult Participants Without HIV

Phase 1

Active, not recruiting

Conditions: HIV

Interventions: Biological: N332-GT5 gp140 (IM, Bolus)
Biological: N332-GT5 gp140 (SC, Bolus)
Biological: N332-GT5 gp140 (IM, Fractioned)
Biological: N332-GT5 gp140 (SC, Fractioned)
Biological: SMNP (IM, Bolus)
Biological: SMNP (SC, Bolus)
Biological: SMNP (IM, Fractioned)
Biological: SMNP (SC, Fractioned)

First Posted Date: 2023-09-13

Last Posted Date: 2025-06-24

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 57

Registration Number: NCT06033209

Locations: 🇺🇸
Bridge HIV CRS, San Francisco, California, United States
🇺🇸
Atlanta - Hope Clinic, Decatur, Georgia, United States
🇺🇸
Brigham & Women's Hospital, Boston, Massachusetts, United States

and more 5 locations

Phase I Safety Study of B/HPIV3/S-6P Vaccine Via Nasal Spray in Adults

Phase 1

Active, not recruiting

Conditions: SARS-CoV-2 Infection

Interventions: Biological: B/HPIV3/S-6P

First Posted Date: 2023-09-07

Last Posted Date: 2025-03-05

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 27

Registration Number: NCT06026514

Locations: 🇺🇸
Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States

The Study of Immunization in People Living With HIV Undergoing an ATI for Elicitation of VRC01-lineage Antibodies

Phase 1

Recruiting

Conditions: Chronic HIV Infection

Interventions: Biological: 426c.Mod.Core-C4b
Other: Adjuvant 3M-052-AF+Alum

First Posted Date: 2023-08-23

Last Posted Date: 2024-12-13

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 40

Registration Number: NCT06006546

Locations: 🇺🇸
New York Blood Center CRS (Site #31801), New York, New York, United States
🇺🇸
Birmingham, Birmingham, Alabama, United States
🇺🇸
Atlanta- Ponce, Atlanta, Georgia, United States

and more 7 locations

Estradiol Therapy In Transgender Women to Research Interactions With HIV Therapy

Phase 2

Active, not recruiting

Conditions: HIV I Infection

Interventions: Drug: Estradiol

First Posted Date: 2023-08-22

Last Posted Date: 2025-07-02

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 93

Registration Number: NCT06005610

Locations: 🇺🇸
UCSD Antiviral Research Center CRS (701), San Diego, California, United States
🇺🇸
University of California, San Francisco HIV/AIDS CRS (801), San Francisco, California, United States
🇺🇸
University of Colorado Hospital CRS (6101), Aurora, Colorado, United States

and more 20 locations

Trial to Evaluate the Safety, Tolerability, and Immunogenicity of a Mosaic Hexavalent Influenza Vaccine VRC-FLUMOS0116-00-VP (FluMos-v2) in Healthy Adults

Phase 1

Active, not recruiting

Conditions: Influenza

Interventions: Biological: VRC-FLUMOS0116-00-VP( FLUMos-v2)

First Posted Date: 2023-08-01

Last Posted Date: 2025-06-17

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 30

Registration Number: NCT05968989

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

High vs.Standard Dose Influenza Vaccine in Pediatric Solid Organ Transplant (SOT) Recipients

Phase 2

Recruiting

Conditions: Immunization; Infection
Transplantation Infection
Influenza

Interventions: Biological: Standard Dose Quadrivalent Inactivated Influenza Vaccine
Biological: High Dose Quadrivalent Inactivated Influenza Vaccine

First Posted Date: 2023-07-17

Last Posted Date: 2025-03-21

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 312

Registration Number: NCT05947071

Locations: 🇺🇸
Stanford University, Stanford, California, United States
🇺🇸
Children's Healthcare of Atlanta, Atlanta, Georgia, United States
🇺🇸
Ann Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States

and more 5 locations

A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults

Phase 1

Active, not recruiting

Conditions: Influenza

Interventions: Biological: DCVC H1 HA mRNA vaccine
Biological: Quadrivalent Recombinant Seasonal Influenza Vaccine
Other: Sodium Chloride, 0.9%

First Posted Date: 2023-07-14

Last Posted Date: 2025-06-24

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 10

Registration Number: NCT05945485

Locations: 🇺🇸
University of Iowa - Infectious Disease Clinic, Iowa City, Iowa, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy